Akebia Therapeutics Inc.

NASDAQ:AKBA   3:42:58 PM EDT
3.60
-0.08 (-2.17%)
Products

Akebia And Otsuka Announce FDA Acceptance For Filing Of New Drug Application For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis And Not On Dia

Published: 06/01/2021 10:16 GMT
Akebia Therapeutics Inc. (AKBA) - Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis.
Akebia Therapeutics Inc - Vadadustat Assigned PDUFA Target Action Date of March 29, 2022.
Akebia Therapeutics Inc - FDA Also Indicated That They Are Not Currently Planning to Hold an Advisory Committee Meeting to Discuss Application.